Legal Representation
Attorney
Steven E. Lauridsen
USPTO Deadlines
Next Deadline
1897 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20250422)
Due Date
April 22, 2031
Grace Period Ends
October 22, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
32 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Apr 22, 2025 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Apr 22, 2025 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Mar 4, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Mar 4, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Feb 26, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Feb 6, 2025 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Feb 5, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Feb 5, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Feb 5, 2025 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
| Feb 3, 2025 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Feb 3, 2025 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Feb 3, 2025 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Dec 23, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Dec 23, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Dec 23, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Oct 30, 2024 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| Oct 30, 2024 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Jul 31, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jul 31, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jul 31, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jul 1, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jul 1, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jul 1, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Mar 29, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Mar 29, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Mar 29, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Mar 26, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jan 28, 2024 | AMPX | O | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | Loading... |
| Jan 25, 2024 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Sep 6, 2023 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED | Loading... |
| Aug 21, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jul 25, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 001
Chemicals for use in biotechnological manufacturing processes; Chemicals for use in biotechnological product development; Chemical substances for use in the biotechnological industry; media for cell culture for research use in the biotechnological industry; Chemical reagents for use in biotechnology, other than for medical or veterinary use; all of the aforesaid being for use in cell therapy, living cell therapy and the treatment of cancer
Class 005
Biotechnological immune cell preparations for medical use; all of the aforesaid being for use in cell therapy, living cell therapy and the treatment of cancer
Class 042
Biotechnological research; Biotechnology research; Research relating to biotechnology; Biotechnological research relating to industry; Research and development in the field of biotechnology; Research and development in the pharmaceutical and biotechnology fields; Information on the subject of scientific research in the field of biochemistry and biotechnology; all of the aforesaid relating to cell therapy, living cell therapy and the treatment of cancer
Classification
International Classes
001
005
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"IMMUNOMODULATORY" and "NEUTROPHIL"